Literature DB >> 19929797

Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART.

Yolanda M Pacheco1, Inmaculada Jarrín, Julia Del Amo, Santiago Moreno, José A Iribarren, Pompeyo Viciana, Jorge Parra, Juan L Gomez-Sirvent, Félix Gutierrez, José R Blanco, Francesc Vidal, Manuel Leal.   

Abstract

A proportion of HIV-patients does not normally restore their CD4 counts despite virological response to HAART. Those whose CD4 counts persistently remain closed to the critical threshold for opportunistic infections deserve special interest. To study the risk factors, the long-term CD4 counts evolution, and the risk of death of patients who persistently maintain low CD4 counts, despite virological response to HAART, within a multicenter, hospital-based cohort study. A total of 147 patients were selected from CoRIS-MD and classified into a "Low-Group" or a "High-Group", depending on their CD4 counts after two-years of effective HAART (threshold 250 cells/microL). Associated risk factors were analysed by logistic regression, the CD4 dynamics were evaluated over a total period of 7.70 years (IQR, 6.70-9.00), and mortality was estimated by Cox proportional hazard. A total of 40 patients (27%) were classified into the "Low-Group". The odds ratio for this group increased with age, being 4.56 (2.23-9.33) for over 40, and was also higher among IDU, 3.63 (1.04-12.68). Six years thereafter, among these patients, only a 30% exceeded 350 CD4 cells/microL and a 12% exceeded 500 CD4 cells/microL. Furthermore, the "Low-Group" had a death rate of 2.42 per 100 persons/year (95%CI, 1.01-5.81), although once adjusted by age the estimates were no longer significant [4.14 (0.87-19.72)]. Our results suggest that those HIV patients who have not overcome the critical threshold of 250 CD4 cells/microL after a two years period of virologically effective HAART do persist with the aforementioned failure of CD4 restoration for a much longer time.

Entities:  

Mesh:

Year:  2009        PMID: 19929797     DOI: 10.2174/157016209789973673

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  10 in total

1.  Discordance between peripheral and colonic markers of inflammation during suppressive ART.

Authors:  Richard M Dunham; Ivan Vujkovic-Cvijin; Steven A Yukl; Mara J Broadhurst; Pʼng Loke; Rebecca G Albright; Joseph K Wong; Michael M Lederman; Ma Somsouk; Peter W Hunt; Jeffrey N Martin; Steven G Deeks; Joseph M McCune
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

2.  Increased Regulatory T-Cell Percentage Contributes to Poor CD4(+) Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy.

Authors:  Julien Saison; Delphine Maucort Boulch; Christian Chidiac; Julie Demaret; Christophe Malcus; Laurent Cotte; Francoise Poitevin-Later; Patrick Miailhes; Fabienne Venet; Mary Anne Trabaud; Guillaume Monneret; Tristan Ferry
Journal:  Open Forum Infect Dis       Date:  2015-05-01       Impact factor: 3.835

Review 3.  Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.

Authors:  Christine Kelly; Katherine M Gaskell; Marty Richardson; Nigel Klein; Paul Garner; Peter MacPherson
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

4.  Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection.

Authors:  Sophie Seang; Anoma Somasunderam; Maitreyee Nigalye; Ma Somsouk; Timoty W Schacker; Joyce L Sanchez; Peter W Hunt; Netanya S Utay; Jordan E Lake
Journal:  Pathog Immun       Date:  2017-06-21

5.  A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients.

Authors:  Esther Rodríguez-Gallego; Josep Gómez; Yolanda M Pacheco; Joaquim Peraire; Consuelo Viladés; Raúl Beltrán-Debón; Roger Mallol; Miguel López-Dupla; Sergi Veloso; Verónica Alba; Julià Blanco; Nicolau Cañellas; Anna Rull; Manuel Leal; Xavier Correig; Pere Domingo; Francesc Vidal
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

6.  Anti-retroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals.

Authors:  Sushma K Cribbs; David M Guidot; Greg S Martin; Jeffrey Lennox; Lou Ann Brown
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

7.  Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes.

Authors:  Josué Pérez-Santiago; Dan Ouchi; Victor Urrea; Jorge Carrillo; Cecilia Cabrera; Jordi Villà-Freixa; Jordi Puig; Roger Paredes; Eugènia Negredo; Bonaventura Clotet; Marta Massanella; Julià Blanco
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

8.  Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?

Authors:  Inma Jarrin; Nikos Pantazis; Judith Dalmau; Andrew N Phillips; Ashley Olson; Cristina Mussini; Faroudy Boufassa; Dominique Costagliola; Kholoud Porter; Juliá Blanco; Julia Del Amo; Javier Martinez-Picado
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

9.  Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study.

Authors:  Ana-Irene Malo; Anna Rull; Josefa Girona; Pere Domingo; Rocío Fuertes-Martín; Núria Amigó; Cèlia Rodríguez-Borjabad; Neus Martínez-Micaelo; Manuel Leal; Joaquim Peraire; Xavier Correig; Francesc Vidal; Lluis Masana
Journal:  J Clin Med       Date:  2020-05-04       Impact factor: 4.241

10.  Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects.

Authors:  Isaac Rosado-Sánchez; Rebeca De Pablo-Bernal; Anna Rull; Juan Gónzalez; Santiago Moreno; David Vinuesa; Vicente Estrada; María Ángeles Muñoz-Fernández; Francesc Vidal; Manuel Leal; Yolanda María Pacheco
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.